title: The role of pacritinib in the management of myelofibrosis.
abstract: The recent discovery of the JAK2 mutation and its role in the pathogenesis of myeloproliferative neoplasms led to the development of a novel class of therapeutic agents, the oral JAK2 inhibitors. These agents are effective in decreasing organomegaly and ameliorating constitutional symptoms in patients with myelofibrosis, regardless of the mutational status. Among this new class of agents is pacritinib, a dual JAK2 and FLT3 inhibitor that showed evidence of clinical efficacy in early-phase trials of patients with myelofibrosis, with limited hematologic toxicity.
authors.affiliation: University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA.
authors.forename: Vu H
authors.initials: VH
authors.lastname: Duong
authors.forename: Rami S
authors.initials: RS
authors.lastname: Komrokji
mesh_terms: D000818:Animals; D001952:Bridged-Ring Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D053614:Janus Kinase 2 / Q000378:metabolism; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: C561234:11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene; D001952:Bridged-Ring Compounds; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053614:Janus Kinase 2
keywords: FLT3 inhibitor; JAK2 inhibitor; SB1518; essential thrombocythemia; myelofibrosis; myeloproliferative neoplasms; pacritinib; polycythemia vera; ruxolitinib